ecrin-mdr-crcClinical2016IPD Sharing (as of June 2020): NoClinical ResponseColorectal cancerColorectal NeoplasmsSurvivalClinical ResponseColorectal CancerColorectal NeoplasmsSurvivalInterventionalhttps://newmdr.ecrin.org/Study/23420871OxaliplatinCapecitabineMetronomic capecitabineECRIN MDRCompletedfalseStudy of Metronomic Capecitabine and Oxaliplatin Versus XELOX in Egyptian Metastatic Colorectal Cancer PatientsColorectal cancer (CRC) in Egypt is advanced tumors at diagnosis. Although, the dramatic increase in efficacy, reduction of mortality, and improvements in survival by the use of standard doses of chemotherapy, some CRC patients suffer from severe toxicities besides disease progression. Use of chemotherapy less than the maximum tolerated dose, with no prolonged drug free breaks incapacitates the cells to engage in progression mechanisms, suggesting that it could be a better alternative to standard dose therapy with better toxicity profile2016-01-152342087NCT04425564